Please ensure Javascript is enabled for purposes of website accessibility

Why Tilray Shares Jumped Today

By Keith Speights - Oct 24, 2019 at 4:45PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors cheered the company's export of medical cannabis to the U.S.

What happened

Shares of Tilray (TLRY) were jumping 10.3% higher as of 3:22 p.m. EDT on Thursday. The nice gain came after the Canadian cannabis producer announced that it has exported medical cannabis to the United States for a clinical study.

Tilray said this study, which is being led by scientists at Columbia University Irving Medical Center (CUIMC) in New York, will evaluate the use of medical cannabis in patients with breast cancer who suffer from taxane-induced peripheral neuropathy (TIPN), a disorder where nerve damage resulting from chemotherapy causes numbness or pain.

So what

What does Tilray's news mean for investors? Not much, at least not at this point. However, it was good news for Tilray, since the company hasn't had much positive going for it so far this year.

Cannabis leaf and a stethescope

Image source: Getty Images.

Philippe Lucas, Tilray's Vice President of Global Patient Research and Access, said that the company is "excited to support this groundbreaking, first-of-its-kind trial seeking to find a new treatment option for TIPN." Dr. Margaret Haney, one of the two lead scientists on the clinical study at CUIMC, noted, "There is exciting preclinical evidence showing that THC and CBD significantly reduce TIPN, and our study will be the first to test this in a well-powered clinical trial."

More than two-thirds of women who receive chemotherapy to treat breast cancer suffer from TIPN. The condition can even result in some patients being forced to abandon treatment by chemotherapy. 

If the CUIMC clinical study proves to be successful, it could bode well for the cannabis industry overall. Tilray would likely benefit, especially considering the company's focus on medical cannabis research and its partnership with pharmaceutical giant Novartis. However, it remains to be seen if cannabis is beneficial in helping breast cancer patients with TIPN. 

Now what

For now, Tilray's primary challenge is to improve its bottom line. The company continues to lose money and is burning through its cash stockpile. Today's news about the CUIMC clinical study highlights the main issue for marijuana stocks like Tilray: There's a lot of potential but it has yet to be realized. 

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Tilray Stock Quote
Tilray
TLRY
Novartis AG Stock Quote
Novartis AG
NVS
$87.15 (1.41%) $1.21

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
379%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/10/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.